C13orf15

Revision as of 14:54, 4 September 2012 by WikiBot (talk | contribs) (Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}}))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search


Response gene to complement 32
Identifiers
Symbols RGC32 ; KIAA0564; MGC87338; bA157L14.2
External IDs Template:OMIM5
RNA expression pattern
More reference expression data
Orthologs
Template:GNF Ortholog box
Species Human Mouse
Entrez n/a n/a
Ensembl n/a n/a
UniProt n/a n/a
RefSeq (mRNA) n/a n/a
RefSeq (protein) n/a n/a
Location (UCSC) n/a n/a
PubMed search n/a n/a

Response gene to complement 32, also known as RGC32, is a human gene.[1]

This gene is thought to regulate cell cycle progression. It is induced by p53 in response to DNA damage, or by sublytic levels of complement system proteins that result in activation of the cell cycle. The encoded protein localizes to the cytoplasm during interphase and to centrosomes during mitosis. The protein forms a complex with polo-like kinase 1. The protein also translocates to the nucleus in response to treatment with complement system proteins, and can associate with and increase the kinase activity of cell division cycle 2 protein. In different assays and cell types, overexpression of this protein has been shown to activate or suppress cell cycle progression.[1]

References

  1. 1.0 1.1 "Entrez Gene: RGC32 response gene to complement 32".

Further reading

  • Fosbrink M, Niculescu F, Rus H (2005). "The role of c5b-9 terminal complement complex in activation of the cell cycle and transcription". Immunol. Res. 31 (1): 37–46. PMID 15591621.
  • Bonaldo MF, Lennon G, Soares MB (1997). "Normalization and subtraction: two approaches to facilitate gene discovery". Genome Res. 6 (9): 791–806. PMID 8889548.
  • Badea TC, Niculescu FI, Soane L; et al. (1998). "Molecular cloning and characterization of RGC-32, a novel gene induced by complement activation in oligodendrocytes". J. Biol. Chem. 273 (41): 26977–81. PMID 9756947.
  • Badea T, Niculescu F, Soane L; et al. (2002). "RGC-32 increases p34CDC2 kinase activity and entry of aortic smooth muscle cells into S-phase". J. Biol. Chem. 277 (1): 502–8. doi:10.1074/jbc.M109354200. PMID 11687586.
  • Strausberg RL, Feingold EA, Grouse LH; et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMID 12477932.
  • Ota T, Suzuki Y, Nishikawa T; et al. (2004). "Complete sequencing and characterization of 21,243 full-length human cDNAs". Nat. Genet. 36 (1): 40–5. doi:10.1038/ng1285. PMID 14702039.
  • Dunham A, Matthews LH, Burton J; et al. (2004). "The DNA sequence and analysis of human chromosome 13". Nature. 428 (6982): 522–8. doi:10.1038/nature02379. PMID 15057823.
  • Gerhard DS, Wagner L, Feingold EA; et al. (2004). "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)". Genome Res. 14 (10B): 2121–7. doi:10.1101/gr.2596504. PMID 15489334.
  • Fosbrink M, Cudrici C, Niculescu F; et al. (2005). "Overexpression of RGC-32 in colon cancer and other tumors". Exp. Mol. Pathol. 78 (2): 116–22. doi:10.1016/j.yexmp.2004.11.001. PMID 15713436.
  • Tanaka T, Takada H, Nomura A; et al. (2005). "Distinct gene expression patterns of peripheral blood cells in hyper-IgE syndrome". Clin. Exp. Immunol. 140 (3): 524–31. doi:10.1111/j.1365-2249.2005.02805.x. PMID 15932515.
  • Olsen JV, Blagoev B, Gnad F; et al. (2006). "Global, in vivo, and site-specific phosphorylation dynamics in signaling networks". Cell. 127 (3): 635–48. doi:10.1016/j.cell.2006.09.026. PMID 17081983.
  • Saigusa K, Imoto I, Tanikawa C; et al. (2007). "RGC32, a novel p53-inducible gene, is located on centrosomes during mitosis and results in G2/M arrest". Oncogene. 26 (8): 1110–21. doi:10.1038/sj.onc.1210148. PMID 17146433.

Template:WikiDoc Sources